Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiol Therapeutics (CRDL) Liabilities and Shareholders Equity (2020 - 2026)

Cardiol Therapeutics filings provide 3 years of Liabilities and Shareholders Equity readings, the most recent being $45.7 million for Q4 2022.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 34.45% to $45.7 million in Q4 2022 year-over-year; TTM through Dec 2022 was $219.1 million, a 75.51% increase, with the full-year FY2022 number at $45.7 million, down 34.45% from a year prior.
  • Liabilities and Shareholders Equity hit $45.7 million in Q4 2022 for Cardiol Therapeutics, down from $52.4 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $69.7 million in Q4 2021 to a low of $12.2 million in Q4 2020.
  • Median Liabilities and Shareholders Equity over the past 3 years was $49.1 million (2022), compared with a mean of $44.5 million.
  • Biggest five-year swings in Liabilities and Shareholders Equity: soared 471.86% in 2021 and later plummeted 34.45% in 2022.
  • Cardiol Therapeutics' Liabilities and Shareholders Equity stood at $12.2 million in 2020, then soared by 471.86% to $69.7 million in 2021, then plummeted by 34.45% to $45.7 million in 2022.
  • The last three reported values for Liabilities and Shareholders Equity were $45.7 million (Q4 2022), $52.4 million (Q3 2022), and $58.2 million (Q2 2022) per Business Quant data.